Curative effect analysis of different treatments for gefitinib-resistance advanced non-small cell lung cancer patients.

OBJECTIVE: Gefitinib is effective epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) for advanced non-small cell lung cancer (NSCLC) patients, but with the drug use, inevitable gefitinib-resistance and severe complications were observed and resulted in failure treatments. The purpose of the present study was to investigate the curative effect of different treatment of navelbine plus cisplatin in combination with gefitinib and gefitinib single on gefitinib-resistance advanced NSCLC patients.

METHODS: Total Of 120 patients acquired gefitinib-resistance NSCLC patients treated in Taian City Central Hospital of Shandong province from May, 2010 to June, 2014 were incorporated in our study according to the inclusion and exclusion criteria. The patients were divided into chemotherapeutical group and gefitinib group and the mean follow-up was 12 months (6-39 months), the information of patients was recorded as gender, age, smoking, complications, hepatic metastasis, bone metastasis, brain metastasis and acquired chemotherapy or not. Chi-square test and t-test were performed to analyzed collection data, Log-rank was analyzed significance of survival time among groups and Cox regression was evaluated independent risk factors of survival analysis.

RESULTS: The survival time of chemotherapy group was significantly longer than gefitinib group; the survival time among the two groups was 29.06 and 15.23 months (P<0.05), respectively. Multivariate Cox regression analyzed that lesion's metastasis (hepatic metastasis, bone metastasis and brain metastasis) and acquired chemotherapy were independent risk factors influence on patients overall survival time; gender, age, smoking, complications had no significance influence on survival time between the two groups.

CONCLUSION: Lesion's metastasis and acquired chemotherapy were independent risk factors influence on patients' overall survival time and the survival time of chemotherapy group was significantly longer than gefitinib group.